Galvani Bioelectronics
See the following -
Digital health round-up: bioelectronics are closer than you think
Towards the end of last year, Google’s life sciences division Verily and GlaxoSmithKline co-founded Galvani Bioelectronics to develop medicines that harness electrical signals in the body to treat chronic diseases like asthma, arthritis and even gastrointestinal diseases. At the time, the unveiling of Galvani felt like a new frontier in medicine and, though somewhat difficult to comprehend, something that could genuinely change the lives of millions of people worldwide...
- Login to post comments
Pharma and Tech Giants Team Up to Design Devices That Can Hack Your Body’s Electrical Signals
Electrical signals from the brain govern much of what goes on in the human body. Pharma and tech giants are spending big money to figure out how to hack these signals, a burgeoning field known as “bioelectronics.” GlaxoSmithKline and Verily Life Sciences, an Alphabet subsidiary, are investing more than $700 million over seven years to create a new company, Galvani Bioelectronics. The firm, 55 percent owned by GSK, will have one lab in Stevenage, U.K., and another in San Francisco...
- Login to post comments